Genedrive PLC (GB:GDR)
LSE:GDR
Top Page
Genedrive
(LSE:GDR)
Select Model
Select Model
Rating:47Neutral
Price Target:
0.96 p
▲(9.09% Upside)
Action:ReiteratedDate:01/22/26
The score is held back primarily by weak financial performance—large ongoing losses, sustained cash burn, and a shrinking equity base despite minimal debt. Technicals are moderately supportive with price above key moving averages and positive MACD, but elevated RSI signals near-term overheating risk. Valuation remains challenging due to negative earnings (negative P/E).
Positive Factors
Recurring consumables model
Genedrive’s revenue mix includes instrument sales plus recurring single-use test kits, creating a consumables annuity as installed bases grow. That structural model supports steadier long-term revenue and margin expansion if kit adoption scales across healthcare sites.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow (~-£5.1m) shows the business cannot self-fund growth today. Continued cash burn forces reliance on external financing, which risks dilution or constrained investment in commercialisation if capital markets tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables model
Genedrive’s revenue mix includes instrument sales plus recurring single-use test kits, creating a consumables annuity as installed bases grow. That structural model supports steadier long-term revenue and margin expansion if kit adoption scales across healthcare sites.
Read all positive factors
Genedrive (GDR) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£15.65M
Dividend YieldN/A
Average Volume (3M)49.58M
Price to Earnings (P/E)―
Beta (1Y)-1.39
Revenue Growth90.42%
EPS Growth79.21%
CountryUK
Employees43
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,605,568,200
10 Day Avg. Volume14,118,826
30 Day Avg. Volume49,583,488
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)5.48
Price to Sales (P/S)10.31
P/FCF Ratio-1.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Genedrive Business Overview & Revenue Model
Company Description
genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive, a patented...
How the Company Makes Money
Genedrive makes money primarily by selling its genedrive diagnostic platform and the associated consumable test kits (assays) that run on the instrument. The revenue model is typically a combination of (1) capital/equipment revenue from instrument...
Genedrive Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 764.00K | 501.00K | 55.00K | 49.00K | 687.00K |
| Gross Profit | 764.00K | 254.00K | -199.00K | -3.82M | -3.82M |
| EBITDA | -5.36M | -7.49M | -5.70M | -5.37M | -1.37M |
| Net Income | -5.23M | -7.08M | -5.15M | -4.67M | -691.00K |
Balance Sheet | |||||
| Total Assets | 2.81M | 6.80M | 4.51M | 6.62M | 4.88M |
| Cash, Cash Equivalents and Short-Term Investments | 1.18M | 5.19M | 2.60M | 4.59M | 2.57M |
| Total Debt | 0.00 | 19.00K | 241.00K | 16.00K | 119.00K |
| Total Liabilities | 1.38M | 1.44M | 2.47M | 1.01M | 1.28M |
| Stockholders Equity | 1.44M | 5.36M | 2.04M | 5.61M | 3.59M |
Cash Flow | |||||
| Free Cash Flow | -5.12M | -3.80M | -3.83M | -4.67M | -5.29M |
| Operating Cash Flow | -5.10M | -3.77M | -3.78M | -4.61M | -5.18M |
| Investing Cash Flow | -23.00K | 1.00K | -37.00K | 45.00K | 33.00K |
| Financing Cash Flow | 1.12M | 6.36M | 1.82M | 6.58M | -456.00K |
Genedrive Technical Analysis
Negative
0.88
Price Trends
1.05
Negative
0.98
Positive
0.92
Positive
Market Momentum
>-0.01
Positive
43.59
Neutral
45.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:GDR, the sentiment is Negative. The current price of 0.88 is below the 20-day moving average (MA) of 1.03, below the 50-day MA of 1.05, and below the 200-day MA of 0.92, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 43.59 is Neutral, neither overbought nor oversold. The STOCH value of 45.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:GDR.
Genedrive Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | £101.74M | 55.78 | 3.01% | ― | -1.43% | 28.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £1.10B | -8.50 | -29.43% | ― | 22.03% | 20.01% | |
47 Neutral | £15.65M | -1.51 | -153.92% | ― | 90.42% | 79.21% | |
45 Neutral | £18.20M | -2.69 | -58.27% | ― | 37.39% | -126.19% | |
40 Underperform | £16.18M | -6.19 | -213.66% | ― | 39.88% | 81.33% | |
39 Underperform | £10.27M | -0.47 | 425.97% | ― | -4.48% | 61.09% |
* Healthcare Sector Average
GB:GDR
Genedrive
0.98
-0.54
-35.52%
GB:EKF
EKF Diagnostics Holdings
23.60
1.60
7.27%
GB:RENX
Renalytix
2.35
-6.65
-73.89%
GB:ABDX
Abingdon Health PLC
7.25
0.75
11.54%
GB:APTA
Aptamer Group Plc
0.60
0.34
130.77%
GB:ONT
Oxford Nanopore Technologies PLC
113.60
11.30
11.05%
Genedrive Corporate Events
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Genedrive shareholders back fundraising as company expands pharmacogenetic footprint
Positive
Mar 9, 2026
Genedrive plc, a Manchester‑based pharmacogenetic testing specialist, develops and commercialises rapid, low‑cost point‑of‑care genetic tests that enable clinicians to tailor drug choice and dosage, with a focus on emergenc...
Business Operations and StrategyPrivate Placements and Financing
Genedrive Raises £5.26 Million to Bolster Point-of-Care Pharmacogenetics Push
Positive
Mar 9, 2026
Genedrive plc, a UK-listed point-of-care pharmacogenetic testing specialist, focuses on rapid, low-cost genetic diagnostics that enable clinicians to tailor drug choice and dosage, with particular emphasis on emergency healthcare settings. The com...
Delistings and Listing ChangesPrivate Placements and FinancingShareholder Meetings
Genedrive completes £500,000 placing as part of wider AIM fundraising
Positive
Feb 13, 2026
Genedrive has completed a placing of 50,000,000 new shares at 1.0 pence each, raising gross proceeds of £500,000 as part of a wider fundraising package that also includes a proposed £3.5 million direct subscription and an open offer of u...
Business Operations and StrategyPrivate Placements and Financing
Genedrive launches £5.5m fundraise to drive pharmacogenetic growth
Negative
Feb 13, 2026
Genedrive plc plans to raise up to £5.5 million through a combination of a direct subscription, a conditional placing and an open offer to existing shareholders, all priced at 1.0 pence per new share, a 7.4% discount to the latest closing pri...
Business Operations and StrategyPrivate Placements and Financing
Genedrive Wins Major Shareholder Backing for Up to £6m Equity Raise to Fund Growth
Positive
Jan 19, 2026
Genedrive plc has secured strong indicated backing from its largest shareholder David Nugent and significant shareholder Robert English for an equity financing of up to £6 million, with each committing to subscribe £1.5 million and Nugen...
Business Operations and StrategyShareholder Meetings
Genedrive Wins Shareholder Backing for All AGM Resolutions
Positive
Dec 31, 2025
Genedrive plc, a UK-based specialist in point-of-care pharmacogenetic testing for emergency and personalised medicine, has built a product suite around its Genedrive MT-RNR1 ID Kit for rapid antibiotic decision-making in neonatal intensive care an...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.